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Paul Shaughnessy,1 Miguel Islas-Ohlmayer,1 Julie Murphy,2 Maureen Hougham,1
Jill MacPherson,1 Kurt Winkler,1 Matthew Silva,3 Michael Steinberg,3 Jeffrey Matous,2
Sheryl Selvey,3 Michael Maris,2 Peter A. McSweeney21Plerixafor plus granulocyte-colony stimulating factor (G-CSF) has been shown tomobilize moreCD34 cells
than G-CSF alone for autologous hematopoietic stem cell transplantation (HSCT). However, many centers
use chemotherapy followed byG-CSF tomobilize CD341 cells prior toHSCT.We performed a retrospective
study of patients who participated in the expanded access program (EAP) of plerixafor and G-CSF for initial
mobilization of CD341 cells, and compared outcomes to matched historic controls mobilized with cyclo-
phosphamide 3-5 g/m2 and G-CSF at 2 centers that participated in the EAP Control patients were matched
for age, sex, disease, disease stage, and number of prior therapies. Mobilization costs were defined to be
the costs of medical procedures, resource utilization, and medications. Median national CMS reimbursement
rates were used to establish the costs of procedures, hospitalization, provider visits, apheresis, CD341 cell
processing and cryopreservation. Average sale price was used for G-CSF, plerixafor, cyclophosphamide,
MESNA, antiemetics, and antimicrobials. A total of 33 patients from the EAP and 33 matched controls
were studied. Two patients in the control group were hospitalized for neutropenic fever during the mobiliza-
tion period. Apheresis started on the scheduled day in 33 (100%) study patients and in 29 (88%) control pa-
tients (P 5 0.04). Sixteen (48%) control patients required weekend apheresis. There was no difference in
number of CD341 cells collected between the groups, and all patients proceeded to HSCTwith no difference
in engraftment outcomes. Median total cost of mobilization was not different between the plerixafor/G-CSF
and control groups ($14,224 versus $18,824; P5.45). In conclusion, plerixafor/G-CSF and cyclophosphamide/
G-CSF for upfront mobilization of CD342 cells resulted in similar numbers of cells collected, costs of mobi-
lization, and clinical outcomes. Additionally, plerixafor/G-CSF mobilization resulted in more predictable days
of collection, no weekend apheresis procedures, and no unscheduled hospital admissions.
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High-dose chemotherapy and autologous hemato-
poietic stem cell transplantation (HSCT) is an integral
part of treatment for patients with multiple myeloma
(MM), relapsed Hodgkin’s disease (HD), and non-
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6/j.bbmt.2010.08.018hematopoietic stem cells (HSC) into the peripheral
blood using chemotherapy and/or cytokines followed
by apheresis is the most common method used by
many centers for autologous HSC collection [4-6].
Prior studies have shown that more HSC are
mobilized following chemotherapy and cytokine
administration compared to cytokine administration
alone [7-10]. Some patients who receive chemotherapy
as part of standard therapy can also have HSC
collected as they recover from their standard therapy.
However, there may be greater toxicity or risk of
infection following chemotherapy mobilization [8].
The method used for HSC mobilization has not been
shown to affect overall transplantation outcomes, and
choice of method may be more dependent on institu-
tional practice [4,7-11].
Plerixafor is a small molecule that reversibly
inhibits chemokine stromal cell derived factor 1 alpha729
730 Biol Blood Marrow Transplant 17:729-736, 2011P. Shaughnessy et al.(SDF-1alpha) binding to CXC chemokine receptor 4
(CXCR4), resulting in increased HSC migration into
peripheral blood circulation [12]. Randomized studies
have shown that the combination of granulocyte colony
stimulating factor (G-CSF) and plerixafor mobilizes
more HSC in fewer apheresis sessions compared to
G-CSF alone in MM and NHL patients [13,14].
However, many centers continue to use chemotherapy
followed by G-CSF for HSC mobilization, and
no prospective randomized studies comparing the
mobilization efficacy of G-CSF 1 chemotherapy and
G-CSF1 plerixafor have been published.
The expanded access program (EAP) was a study
using G-CSF1 plerixafor for the front-line mobiliza-
tion and collection of peripheral blood stem cells for
autologous HSCT in patients with NHL, HD, and
MM. The EAP created a database of clinical outcomes
using plerixafor-based mobilization at multiple trans-
plant centers. Two centers that participated in the
EAP also had similar chemotherapy mobilization
processes that allowed for this retrospective review of
patients mobilized with G-CSF 1 plerixafor com-
pared to matched controls mobilized with G-CSF 1
chemotherapy. Because the efficacy of G-CSF and
plerixafor for mobilization has been previously estab-
lished, the primary objective of this study was to com-
pare the costs and logistical issues of autologous HSC
mobilization between the 2 methods.PATIENTS AND METHODS
Patients
The EAP was approved by the institutional review
boards (IRBs) at the Texas Transplant Institute and
the Rocky Mountain Blood and Marrow Transplant
Program, and all patients were provided written in-
formed consent. Retrospective analysis for all
patients and controls was separately approved by the
IRBs at both institutions.Figure 1. Chemotherapy mobilizationThe EAP patients were accrued to the study from
July 2008 through January of 2009 and were consecu-
tively treated during this time frame. Eligibility criteria
for the EAP included patients with NHL, MM, or
HD, who were otherwise eligible for autologous
HSC transplantation and had not undergone prior
stem cell mobilization or autologous or allogeneic
HSC transplantation. Study patients also had to be at
least 4 weeks from prior chemotherapy and 2 weeks
from prior cytokine therapy, and have \20% bone
marrow involvement with disease. Controls for the
EAP patients treated at each institution were matched
from the same institution for age, sex, diagnosis, prior
therapy, and stage of disease at time of transplantation.
Control patients also could not have undergone prior
stem cell mobilization or autologous or allogeneic
HSC transplantation. The controls were chosen with-
out knowledge of mobilization outcomes, other than
they subsequently proceeded to autologous transplan-
tation. This was to avoid selecting any controls who
failed mobilization and thus would not have allowed
for valid cost comparisons because of their lack of
apheresis procedures.Mobilization Regimens
Control patients received cyclophosphamide
(CTX) 3-5 g/m2 with equal doses of MESNA, and
G-CSF (10 mg/kg subcutaneously [s.c.]) daily was ini-
tiated the following day. Apheresis was scheduled for
10 days after starting G-CSF in the control patients,
but the actual start of apheresis was based on the
peripheral blood CD341 cell count reaching $10
cells/mL (Figure 1). Patients in the EAP received
G-CSF (10 mg/kg s.c.) daily for 5 days and plerixafor
(0.24 mg/kg s.c.) on the evening of day 4, 11 hours
prior to the initiation of apheresis the next day. Plerix-
afor, G-CSF, and apheresis were repeated daily, for up
to 4 additional apheresis, or until a minimum of 5 
106 CD341 cells/kg were collected for NHL or HDdosing regimen (control patients).
Figure 2. Perixafor mobilization dosing regimen (EAP study patients).
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MM patients (Figure 2).Cost Determination
Data on costs incurred from mobilization and
apheresis were analyzed for all patients in the study
and control groups. Individualized costs were identi-
fied per patient in both groups including all reimburs-
able procedures and charges along with complete costs
of all medications during mobilization. A subanalysis
was performed to evaluate the cost of mobilization in
the study and control groups by capping all costs
once a threshold of 3  106 CD341 cells/kg was
reached for NHL patients, and 6  106 CD341 cells/
kg was reached for MM patients. Another subanalysis
evaluated the cost of mobilization for each apheresis
day. Mobilization costs were divided per treatment
phases into preapheresis and periapheresis costs. The
procedures and costs related to these 2 phases are out-
lined inTable 1 and are adjusted to reflect 2009 dollars.
Costs bundled with chemotherapy included drug ac-
quisition costs, administration, and catheter placement
and removal. Mobilization costs included acquisition
cost of mobilizing agents, administration, routine labTable 1. Procedure Costs
Preapheresis
Chemotherapy associated costs
G-CSF–associated costs
Plerixafor-associated costs
CD34+ (flowcytometry + immunohistochemistry)
Resource utilization (provider visits)
Room costs
Transfusion costs (platelet and PRBC), includes administration
Complete blood count (CBC), Chem-7, microbiology lab costs
Periapheresis
Apheresis
CD34+ (flowcytometry + immunohistochemistry)
Cryopreservation bag storage, supplies, preparation
PRBC indicates packed red blood cells; G-CSF, graulocyte-colony stimulatingmonitoring, and apheresis-related costs. Apheresis-
related costs included the apheresis procedure, flow
cytometry, and immunohistochemistry and related
materials. Mobilization-related hospitalization costs
were based on a flat cost per day of hospitalization.
This analysis was designed to estimate the potential
costs of mobilization procedures from the perspective
of the facility or institution. Procedure charges are
variable and reflect institutional overhead and profit
margin, making charges less useful when trying to de-
fine the costs or value associatedwith offering a service.
Alternatively, institution-specific overhead and direct
costs associated with procedures and services are
proprietary, not released to the public domain, and
cannot be generalized.We chose to avoid the problems
associated with charges and institution-specific costs by
estimating the institutional cost and value of mobiliza-
tion using a standard set of reimbursements for specific
procedures set by the United States (US) Department
of Health and Human Services Centers for Medicaid
Services (HHS/CMS). The US HHS/CMS database
was used to estimate the average reimbursement for pro-
cedures based on national carrier data andwas applied to
reimbursable procedures associated with mobilization
(http://www.cms.gov/PhysicianFeeSched/) [15].MedianChemotherapy i.v. infusion 1 h $143.44
Additional hour of chemotherapy $32.74
Catheter insertion $875.53
Place needle in vein $23.65
Catheter removal $352.02
Immunotherapy injections $12.29
Observation hospital same date $165.70 per day
Immunotherapy injections $12.29
$76.49 + $55.71
$165.70 per visit
$943.02 per day
$538.46 each (platelet and PRBC)
$101.67 each (CBC, Chem-7, microbiology)
$2,048.32
$76.49 + $55.71
$1361.54 for initial bag and $28.00 per each subsequent bag
factor.
Table 2. Average Sale Price (ASP) Medication Costs
Dose/Route ASP Cost
Cyclophosphamide 500 mg i.v.
1 g i.v.
2 g i.v.
$24.27
$43.70
$78.64
G-CSF 300mg/mL, 1 mL s.q.
300mg/mL, 0.5 mL s.q.
480mg/mL, 1.6 mL s.q.
480mg/mL, 0.5 mL s.q.
$207.74
$227.95
$330.86
$363.07
Plerixafor 20 mg/mL, 1.2 mL s.q. $6,250.00
MESNA 1 g i.v. $105.95
Levofloxacin 500 mg, 10 doses/card $9.38 per dose
Fluconazole 400-mg tablet $1.13 per tablet
Acyclovir 400-mg tablet $0.18 per tablet
Cefazolin 1-g vial i.v. $4.87
Ceftriaxone 2 g i.v. $99.68
Ciprofloxacin 500 mg, 20 doses/card $99.42
Azithromycin 250-mg tablet
500-mg tablet
$7.36
$33.62
Prochlorperazine 5 mg/mL, 2 mL i.v. $2.40
Lorazepam 2 mg/mL, 1 mL i.v. $2.04
Vancomycin 1 g i.v. $5.34
Dexamethasone 20 mg/mL $3.58
Granisetron 1 mg/mL, 1 mL $40.00
Ondansetron 32 mg/50 mL i.v.
2 mg/mL, 2 mL p.o.
$191.66
$96.26
p.o. indicates orally; i.v., intravenously, s.q., subcutaneously; G-CSF,
graulocyte-colony stimulating factor.
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mobilization and hospitalization-related procedures,
provider visits, apheresis procedures, CD341 cell
processing, and cryopreservation costs. Procedures
or outcomes that were not reimbursable by CMS
were derived from other cost-methodology studies
[16] and adjusted by 3.5% yearly for inflation from
the year noted in the publication.
Chemotherapeutic agents (cyclophosphamide),mo-
bilizing agents (G-CSF and plerixafor), and supportive
medications (antimicrobials, antiemetics, andMESNA)
were included in the cost analysis. Average wholesale
price (AWP) was used to establish medication acquisi-
tion costs and AWP figures were derived from the
Redbook 2009 edition, using July pricing updates;
AWP was then adjusted to estimate the average sale
price (ASP) that was applied to all medications. ASP
was used for medication pricing to account for lower
thanAWPprices observed in larger institution purchas-
ing groups after applying incentives, rebates, and vol-
ume discounts [17]. There is no centralized source for
ASP, so conversion of AWP to ASP was required for
this analysis using a simple calculation: ASP 5 AWP –
(AWP  0.2); reflecting an estimated 20% margin of
difference between the 2 price indicators. The ASP
used in this study formedications related tomobilization
is listed in Table 2 and adjusted to reflect 2009 dollars.Table 3. Patient Characteristics
Plerixafor/G-CSF
n 5 33
Chemo/G-CSF
n 5 33 P Value
Age median N (range) 58 (41-66) 59 (41-69) .22
Gender N (%)
Male 17 (51.5) 17 (51.5) 1.00
Female 16 (48.5) 16 (48.5) 1.00Statistical Analysis
Patient data was electronically recorded in a rela-
tional database and aggregated for clinical and cost
comparisons. All statistical calculations were performed
with JMP version 8.0.2 by SAS Institute (Cary, NC).
Patient baseline demographic characteristics were
defined with descriptive statistics. Tests for central ten-
dency were selected after reviewing distributions.
Means and standard deviations were applied to nor-
mally distributed variables, and medians were used for
nonnormally distributed variables. Analysis of variance
(ANOVA) and the t test was applied to linear variables
that were normally distributed. Wilcoxon/Kruskal-
Wallis rank-sumwas used to compare medians. Prespe-
cified statistical analysis with Pearson’s chi-squared or
Fisher’s exact test was used for proportional compari-
sons as appropriate. All P values were 2 sided, and alpha
values #0.05 were considered significant.Diagnosis N (%)
MM 20 (60.6) 20 (60.6) 1.00
NHL 13 (39.4) 13 (39.4) 1.00
Lines of prior therapy N (%)
1 20 (60.6) 21 (63.6) .80
2 10 (30.3) 10 (30.3) 1.00
3 3 (9.1) 1 (3.0) .30
4 0 (0) 1 (3.0) 1.00
Chemo indicates chemotherapy (cyclophosphamide 3-5 g/m2); MM,
multiple myeloma; NHL, non-Hodgkins lymphoma; G-CSF, graulocyte
colony stimulating factor.RESULTS
Patient and Control Characteristics
The characteristics of the study and control pa-
tients are listed in Table 3. Nine study patients were
matched with 9 controls at the Texas Transplant
Institute, and 24 study patients were matched with24 controls at the Rocky Mountain Blood andMarrow
Transplant Program. The majority of patients and
controls treated at both centers had MM (61%) and
the remainder hadNHL (39%). The study and control
patients were well matched for age, sex, disease, disease
stage, and lines of prior therapy, with no significant
differences between the groups. Prior therapy in MM
patients included lenalidomide in 11 (33%) EAP
patients and 5 (15%) control patients (P 5 .15). Prior
radiation therapy was delivered to 4 (12%) EAP pa-
tients and 2 (6%) control patients (P 5 .67).Mobilization Outcomes
All patients collected sufficient CD341 cells to
proceed to transplantation (minimum of 2  106
CD341 cells/kg) with no significant difference in
Table 4. Mobilization and Apheresis Results
Plerixafor/G-CSF
n 5 33
Chemo/G-CSF
n 5 33 P Value
Median total CD34+ cells  106/kg, n (range) 10.7 (3.5-37.9) 11.6 (2.1-69.3) .5
Number of patients collecting $2  106 CD34+ cells/kg (%) 33 (100%) 33 (100%) —
Number of patients collecting $5  106 CD34+ cells/kg (%) 31 (94%) 25 (76%) .04
Number of MM patients collecting $ 3  106 CD 34+ cells/kg (%) 13/13 (100%) 11/13 (85%) .14
Number of MM patients collecting $6  106 CD 34+ cells/kg (%) 20/20 (100%) 18/20 (90%) 0.49
Median number of apheresis days (range) 1 (1-4) 1 (1-4) .45
Number of patients initiating apheresis on scheduled day (%) 33 (100%) 29 (88%) .04
Number of patients requiring weekend apheresis (%) 0 16 (48%) #.0001
Total number of weekend apheresis procedures 0 19 #.0001
Chemo indicates chemotherapy (cyclophosphamide 3-5 g/m2); MM, multiple myeloma; NHL, non-Hodgkin lymphoma; G-CSF, graulocyte-colony
stimulating factor.
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groups (Table 4). Significantly more patients in the
study group collected $5  106 CD341 cells/kg
than in the control group (n 5 31, 94% and n 5 25,
76%, [P 5 0.04], respectively) (Table 4).
The median total number of days of apheresis was
similar between the groups; however, significantly
more patients in the study group collected on their tar-
geted day of apheresis (33/33, 100%) compared to the
controls (29/33, 88%) (P5 .04) (Table 4). Also, in the
control group, 16 patients required weekend apheresis
based on when they reached the target peripheral
CD341 cell count, whereas no patients in the study
group underwent weekend apheresis (Table 4).
Nineteen patients were hospitalized duringmobili-
zation in the control group for a median of 1 hospital
day (range: 0-2 days), while no patients were hospital-
ized during mobilization in the study group
(Table 5). Seventeen of the 19 control patients were
hospitalized for administration of the chemotherapy
itself, and 2 patients were hospitalized for neutropenic
fever during the nadir from the mobilization chemo-
therapy. Four control patients required packed red
blood cell (PRBC) or platelet transfusions after the
chemotherapy mobilization, whereas no patients
required transfusions in the study group (Table 5).
Significantly more G-CSF was used in the chemother-
apy mobilized patients because of the increased num-
ber of doses of G-CSF used following chemotherapy
(Table 5).Table 5. Mobilization Outcomes
Median G-CSF mcg dose/day (range)
Median total number of G-CSF doses (range)
Median plerixafor dose mg/day (range)
Median number of plerixafor doses (range)
Total number of mobilization-related hospitalizations (%)
Median days of stay for mobilization-related hospitalization
Total number of patients who received transfusions during mobilization (%)
Chemo indicates chemotherapy (cyclophosphamide 3-5 g/m2); MM, multiple
stimulating factor.Mobilization Costs
There was no significant difference in mean or me-
dian total cost of mobilization between the G-CSF 1
plerixafor and G-CSF 1 chemotherapy mobilized pa-
tients. The median periapheresis cost was significantly
less in the study group ($3,626) compared to the
controls ($6,029) (P 5 0.02), but the total median
cost in the study group was not significantly less than
the controls (Table 6). An additional subanalysis was
performed that excluded all costs after arbitrary targets
of 3  106 CD341 cells/kg were collected in NHL
patients and 6  106 CD341 cells/kg were collected
in MM patients, which also resulted in similar mean
and median total costs between the groups (data not
shown).
The median total mobilization costs for patients
separated by their successive days of apheresis are de-
scribed in Figure 3. The median mobilization costs
through a single day of apheresis were less for the
G-CSF 1 plerixafor group ($13,692.00) compared to
the G-CSF 1 chemotherapy group ($15,460.00)
(P 5 0.05). However, the median total cost of mobili-
zation with G-CSF 1 plerixafor was greater for pa-
tients requiring 2 ($24,267 versus $20,601, P 5
0.001), 3 ($35,121 versus $30,869, P 5 0.037), or 4
($45,286 versus $27,144, P 5 0.245) apheresis days,
respectively. Twenty-one of 33 (64%) study patients
completed their apheresis in 1 day compared to 13 of
33 (39%) control patients (P 5 0.049).Plerixafor/G-CSF
n 5 33
Chemo/G-CSF
n 5 33 P Value
780 (600-1440) 900 (480-1260) .82
5 (4-8) 10 (6-17) #.0001
16.8 (13.3-24.4) — —
1 (1-4) — —
0 19 (58) #.0001
0 1 (0-2) #.0001
0 4 (12.1) .06
myeloma; NHL, non-Hodgkin lymphoma; G-CSF, granulocyte-colony
Table 6. Mobilization Costs
Plerixafor/G-CSF
n 5 33
Chemo/G-CSF
n 5 33 P Value
Cost of Pre-Apheresis
Mean $14,676 $12,316 .07
Median (range) $10,627
(9,294-31,445)
$11,939
(7,872-20,810)
.50
Cost of Peri-Apheresis
Mean $5,622 $6,857 .14
Median (range) $3,626
(3,514-14,334)
$6,029
(2,181-15,137)
.02
Total Cost of Mobilization (Pre + Peri-Apheresis)
Mean $20, 298 $19,173 .57
Median (range) $14,224
(12,835-45,779)
$18,824
(10,324-32,195)
.45
Chemo indicates chemotherapy (cyclophosphamide 3 to 5 g/m2).
734 Biol Blood Marrow Transplant 17:729-736, 2011P. Shaughnessy et al.Transplantation Outcomes
All patients in both groups proceeded to transplan-
tation and there was no significant difference in the
time to both neutrophil and platelet engraftment.
The median time to platelet engraftment was 17
(range: 10-61) days in the study group and 14 (range:
10-67) days in the control group. The median time
to neutrophil engraftment was 12 (range: 9-23) days
and 11 (range: 10-13) days in the study and control
groups, respectively.DISCUSSION
Mobilization of autologous hematopoietic progeni-
torsmay be accomplished by cytokines alone,G-CSF1
plerixafor, and chemotherapy-based approaches that
combine chemotherapy with G-CSF or granulocyte
macrophage colony stimulating factor (GM-CSF).
Chemotherapy may be preferred when immediate
control of the underlying disease is required during
the mobilization process. However, studies have also
described the toxicities associated with chemotherapyFigure 3. Total median costs associated with successive days to mobilization.
the indicated day of apheresis and medians were calcultaed for each group in ea
percentile and the lower boundary the 25th percentile; the line represents thused to mobilize autologous HSC, including neutro-
penic fever and sepsis, blood product transfusions,
and bleeding risks [8]. Hospitalization for febrile
neutropenia in cancer patients has been associated
with increased risk of morbidity and mortality, as well
as increased cost [18]. However, situations also exist
that do not require cytotoxic therapy during mobiliza-
tion immediately prior to high-dose chemotherapy and
autologous HSC transplantation. An international
consensus conference has agreed that cytokine-only
mobilization of autologous HSC is adequate for most
patients with well-controlled MM [11]. Also, prior
studies have shown no difference inmalignant cell con-
tamination in apheresis products after chemotherapy
or cytokine only mobilization [19].
This retrospective study of patients mobilized with
G-CSF 1 plerixafor compared to matched historical
controls that underwent G-CSF 1 chemotherapy
mobilization showed similar clinical outcomes in the
number of total CD341 cells collected and transplant
engraftment outcomes. However, G-CSF1 plerixafor
mobilization resulted in more predictable days of col-
lection, no weekend apheresis procedures, and no un-
scheduled hospital admissions. The primary objective
of the EAP was to provide plerixafor to transplant cen-
ters to build experience and safety data of plerixafor in
patients who were otherwise candidates for autologous
HSCT and undergoing first mobilization attempt.
Study and control patients were not necessarily at
high risk for stem cell mobilization failure and had
not failed prior stem cell mobilization, which may
explain the large median dose of stem cells collected.
The prior use of lenalidomide inmultiplemyeloma pa-
tients was similar in both groups and did not seem to
impair stem cell mobilization with either technique.
The total median and mean costs of mobilization
were similar in the G-CSF1 plerixafor andG-CSF1
chemotherapy group in this study. The acquisitionThe total cost of mobilization for each patient was determined through
ch day of apheresis. The upper boundary of the box represents the 75th
e median for each group.
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G-CSF use in the G-CSF1 chemotherapy group. In-
vestigators at both centers agreed that they wouldmost
commonly stopmobilization if$3 106 CD341 cells/
kg were collected in NHL patients, or $6  106 cells/
kgwere collected inMMpatients. Restricting the anal-
ysis to these thresholds found more patients in the
study group reached these minimum CD341 cell/kg
levels; however, the difference was not significant,
and the reevaluation of the cost analysis with these
limits again found no significant difference in total
cost between the groups. Differencesmay exist at other
institutions that could positively or negatively affect
the cost of mobilization after chemotherapy and
G-CSF. For example, waiting to start G-CSF until
several days after the cyclophosphamide is delivered
or using a lower dose of G-CSF may decrease the
cost of G-CSF use. Also, using a different threshold
of peripheral CD341 cell count to trigger starting
apheresis may alter the number of doses of G-CSF
delivered and days of apheresis.
The cost determination in this study attached
CMS reimbursement rates to each procedure for
each patient, and valued each medication associated
with mobilization using ASP. This created a uniform
system for determining the costs of mobilization
with G-CSF 1 plerixafor and G-CSF 1 chemother-
apy. The cost analysis was applied to each individual
patient in both the study and control groups, and
then the mean and median cost for the groups was cal-
culated. The advantage of this methodology allowed
the cost analysis to be done for each day of apheresis
as the number of patients finishing apheresis changed
from day to day. The majority of study patients
(64%) finished apheresis in 1 day compared to only
39% of the control patients, and the total median
cost of mobilization through 1 day of apheresis was
less in the study group. However, the median total
cost of mobilization becomes greater for the G-CSF 1
plerixafor group on the second and subsequent days
of apheresis (Figure 3) because of the added costs of
plerixafor on those days. Therefore, patients who
require repeated dosing of plerixafor for upfront mobi-
lization may have higher costs of mobilization com-
pared to other methods of mobilization.
Additional costs associated with weekend apheresis
procedures were omitted from this cost analysis be-
cause there was no reasonable way to create a general-
ized system for valuing weekend apheresis. CMS does
not recognize differences in reimbursement based on
week days or weekend days. Therefore, no adjustment
to the costs of mobilization between the groups was
made, although significantly more patients receiving
chemotherapy mobilization required apheresis on the
weekend. Many institutions may experience higher
overhead costs associated with weekend mobilization
because of pay differentials for flow cytometry techni-cians, apheresis nurses, and cell therapy lab staff.
There may be an uncalculated cost savings, as well as
staffing and logistical ease that are afforded with
a more predictable start of apheresis after HSC mobi-
lization with G-CSF 1 plerixafor.
In addition to its relatively small size and retro-
spective nature, a limitation of this study is that the
cost estimate does not reflect the actual reimbursement
and institutional overhead associated with mobiliza-
tion from the study centers that participated in this
study, and there may be regional and institutional dif-
ferences in how some CMS and ASP costs are applied.
Another limitation is that the ASP used for medication
costs may underestimate the costs of medications in
smaller facilities that purchase medications in lower
volume or receive fewer discounts, incentives, and re-
bates. Also, the procedures and medications used for
mobilization in this study were done at 2 similar
community-based transplant programs, so differences
in procedures and mobilization regimens used at other
university or nonuniversity-associated centers may
drive cost differences. Some centers collect stem cells
upon recovery from chemotherapy that was delivered
as part of the necessary therapy of the underlying
malignancy and, therefore, may not consider this as
separate mobilization therapy and associated cost.
However, a strength of this study is that by avoiding ac-
tual institutional costs, which are subject to contractual
arrangements and difficult to obtain from institutions,
our standardized costing methodology may be more
broadly applicable to many different types of trans-
plant centers. To our knowledge, this is the first mul-
ticenter report that compares clinical and economic
factors between 2 specific mobilization regimens.
More important than the cost differences in mobi-
lizing autologous HSC is the safety and quality of life
of the patients during the procedures. Significantly
more patients in the G-CSF 1 chemotherapy mobi-
lized group of patients required hospitalization, either
to safely administer the chemotherapy or because of
neutropenic fever. Patients in this group also required
more daily subcutaneous administration of G-CSF
prior to apheresis. The retrospective nature of this
study precluded a formal quality-of-life survey or tox-
icity scoring during the mobilization procedures.
In conclusion, G-CSF 1 plerixafor can mobilize
autologous HSC as well as G-CSF 1 chemotherapy,
with similar transplant engraftment outcomes. The
cost of plerixafor did not increase collection costs over-
all, and can be offset by the increased utilization of
G-CSF after chemotherapy mobilization. G-CSF 1
plerixafor mobilization may also afford patients less
toxicity compared to chemotherapy mobilization,
and provide more predictable days of apheresis, which
could ease hospital or clinic staffing and logistical
issues. To more fully address these questions future
prospective studies with larger numbers of patients
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